<DOC>
	<DOCNO>NCT02222987</DOCNO>
	<brief_summary>Study assess influence 75 mg clopidogrel pharmacodynamics safety 100 mg terbogrel bid .</brief_summary>
	<brief_title>Influence Clopidogrel Pharmacodynamics Safety Terbogrel Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Written inform consent accordance Good Clinical Practice ( GCP ) local legislation Healthy male subject Age &gt; = 18 &lt; = 45 year Broca &gt; = 20 % &lt; = +20 % Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder History orthostatic hypotension , faint spell blackouts Diseases central nervous system ( epilepsy ) psychiatric disorder Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator bleed disorder include prolonged habitual bleeding hematologic disease cerebral bleeding ( e.g . car accident ) commotio cerebri Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within 2 month day prior administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day Alcohol ( &gt; 60 g/day ) abuse Drug abuse Blood donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Any laboratory value outside reference range clinical relevance History familial bleeding disorder Thrombocytes &lt; 150000/Âµl</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>